Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
Pichamol Jirapinyo, Alia Hadefi, Christopher C Thompson, Árpád V Patai, Rahul Pannala, Stefan K Goelder, Vladimir Kushnir, Marc Barthet, Caroline M Apovian, Ivo Boskoski, Christopher G Chapman, Paul Davidson, Gianfranco Donatelli, Vivek Kumbhari, Bu Hayee, Janelle Esker, Tomas Hucl, Aurora D Pryor, Roberta Maselli, Allison R Schulman, Francois Pattou, Shira Zelber-Sagi, Paul A Bain, Valérie Durieux, Konstantinos Triantafyllou, Nirav Thosani, Vincent Huberty, Shelby Sullivan
This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ≥ 30 kg/m2 , or with a BMI of 27...
April 16, 2024: Gastrointestinal Endoscopy
#22
JOURNAL ARTICLE
Jeffrey R Strich, Ahmed Mishuk, Guoqing Diao, Alexander Lawandi, Willy Li, Cumhur Y Demirkale, Ahmed Babiker, Alex Mancera, Bruce J Swihart, Morgan Walker, Christina Yek, Maniraj Neupane, Nathaniel De Jonge, Sarah Warner, Sameer S Kadri
BACKGROUND: The U.S. antibiotic market failure has threatened future innovation and supply. Understanding when and why clinicians underutilize recently approved gram-negative antibiotics might help prioritize the patient in future antibiotic development and potential market entry rewards. OBJECTIVE: To determine use patterns of recently U.S. Food and Drug Administration (FDA)-approved gram-negative antibiotics (ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, plazomicin, eravacycline, imipenem-relebactam-cilastatin, and cefiderocol) and identify factors associated with their preferential use (over traditional generic agents) in patients with gram-negative infections due to pathogens displaying difficult-to-treat resistance (DTR; that is, resistance to all first-line antibiotics)...
April 19, 2024: Annals of Internal Medicine
#23
JOURNAL ARTICLE
Angélica M Rosado-Quiñones, Emilee E Colón-Lorenzo, Zarna Rajeshkumar Pala, Jürgen Bosch, Karl Kudyba, Heather Kudyba, Susan E Leed, Norma Roncal, Abel Baerga-Ortiz, Abiel Roche-Lima, Yamil Gerena, David A Fidock, Alison Roth, Joel Vega-Rodríguez, Adelfa E Serrano
The development of novel antiplasmodial compounds with broad-spectrum activity against different stages of Plasmodium parasites is crucial to prevent malaria disease and parasite transmission. This study evaluated the antiplasmodial activity of seven novel hydrazone compounds (referred to as CB compounds: CB-27, CB-41, CB-50, CB-53, CB-58, CB-59, and CB-61) against multiple stages of Plasmodium parasites. All CB compounds inhibited blood stage proliferation of drug-resistant or sensitive strains of Plasmodium falciparum in the low micromolar to nanomolar range...
April 19, 2024: Antimicrobial Agents and Chemotherapy
#24
REVIEW
Alyssa J Pyun, Philip P Goodney, Jens Eldrup-Jorgensen, James Wadzinski, Eric A Secemsky, Joaquin E Cigarroa
Cardiovascular devices are essential for the treatment of cardiovascular diseases including cerebrovascular, coronary, valvular, congenital, peripheral vascular and arrhythmic diseases. The regulation and surveillance of vascular devices in real-world practice, however, presents challenges during each individual product's life cycle. Four examples illustrate recent challenges and questions regarding safety, appropriate use and efficacy arising from FDA approved devices used in real-world practice. We outline potential pathways wherein providers, regulators and payors could potentially provide high-quality cardiovascular care, identify safety signals, ensure equitable device access, and study potential issues with devices in real-world practice...
April 19, 2024: Catheterization and Cardiovascular Interventions
#25
JOURNAL ARTICLE
Brianna L Spencer, Spencer K Wilhelm, Christopher Stephan, Kristopher A Urrea, Daniela Pelaez Palacio, Robert H Bartlett, Daniel H Drake, Alvaro Rojas-Pena
Cold static storage (CSS) for up to 6 h is the gold standard in heart preservation. Although some hearts stored over 6 h have been transplanted, longer CSS times have increased posttransplant morbimortality. Transmedics® Organ Care System (OCS™) is the only FDA-approved commercial system that provides an alternative to CSS using normothermic ex situ heart perfusion (NEHP) in resting mode with aortic perfusion (Langendorff method). However, it is also limited to 6 h and lacks an objective assessment of cardiac function...
2024: Frontiers in Cardiovascular Medicine
#26
JOURNAL ARTICLE
Aman Kumar Saini, Neha Anil, Ardra N Vijay, Bharti Mangla, Shamama Javed, Pankaj Kumar, Waquar Ahsan
BACKGROUND: Friedreich's ataxia (FRDA) is a rare hereditary neurodegenerative disorder characterized by progressive ataxia, cardiomyopathy, and diabetes. The disease is caused by a deficiency of frataxin, a mitochondrial protein involved in iron-sulfur cluster synthesis and iron metabolism. OBJECTIVE: This review aims to summarize recent advances in the development of treatment strategies for FRDA, with a focus on potential drug candidates and their mechanisms of action...
April 17, 2024: Current Pharmaceutical Design
#27
JOURNAL ARTICLE
Chandani Chandarana, Isha Juwarwala, Shravi Shetty, Anushree Bose
Peptides represent a class of natural molecules with diverse physiological functions, including hormone regulation, neurotransmission, and immune modulation. In recent years, peptide-based therapeutics have gained significant attention in pharmaceutical research and development due to their high specificity, efficacy, and relatively low toxicity. This review provides an overview of the current landscape of peptide drug development, highlighting the challenges faced in their formulation and delivery and the innovative strategies employed to overcome these hurdles...
April 17, 2024: Current Drug Research Reviews
#28
JOURNAL ARTICLE
Daniel Eisenson, Yu Hisadome, Michelle Santillan, Hayato Iwase, WeiLi Chen, Akira Shimizu, Alex Schulick, Du Gu, Armaan Akbar, Alice Zhou, Kristy Koenig, Kasinath Kuravi, Farzana Rahman, Lori Sorrells, Lars Burdorf, Kristina DeSmet, Daniel Warren, Leigh Peterson, Marc Lorber, David Ayares, Andrew Cameron, Kazuhiko Yamada
Xenotransplantation represents a possible solution to the organ shortage crisis and is an imminent clinical reality with long-term xenograft survival in pig-to-nonhuman primate (NHP) heart and kidney large animal models, and short-term success in recent human decedent and clinical studies. However, concerns remain about safe clinical translation of these results, given the inconsistency in published survival as well as key differences between preclinical procurement and immunosuppression and clinical standards-of-care...
April 18, 2024: Nature Communications
#29
REVIEW
Fuduan Chen, Hao Zhong, Ging Chan, Defang Ouyang
Although biopharmaceuticals constitute around 10% of the drug landscape, eight of the ten top-selling products were biopharmaceuticals in 2023. This study did a comprehensive analysis of the FDA's Purple Book database. Firstly, our research uncovered market trends and provided insights into biologics distributions. According to the investigation, although biotechnology has advanced and legislative shifts have made the approval process faster, there are still challenges to overcome, such as molecular instability and formulation design...
April 18, 2024: AAPS PharmSciTech
#30
JOURNAL ARTICLE
Yuting Wen, Jianfeng Wang, Wei Zheng, Jingling Zhu, Xia Song, Taili Chen, Miao Zhang, Zhiwei Huang, Jun Li
Indocyanine green (ICG) is an FDA-approved medical diagnostic agent that is widely used as a near-infrared (NIR) fluorescent imaging molecular probe. However, ICG tends to aggregate to form dimers or H-aggregates in water and lacks physical and optical stability, which greatly decreases its absorbance and fluorescence intensity in various applications. Additionally, ICG has no tissue- or tumor-targeting properties, and its structure is not easy to modify, which has further limited its application in cancer diagnosis...
April 16, 2024: Journal of Colloid and Interface Science
#31
JOURNAL ARTICLE
Didem Akkaya, Gökçe Seyhan, Suat Sari, Burak Barut
Alzheimer's disease (AD), one of the main causes of dementia, is a neurodegenerative disorder. Cholinesterase inhibitors are used in the treatment of AD, but prolonged use of these drugs can lead to serious side effects. Drug repurposing is an approach that aims to reveal the effectiveness of drugs in different diseases beyond their clinical uses. In this work, we investigated in vitro and in silico inhibitory effects of 11 different drugs on cholinesterases. The results showed that trimebutine, theophylline, and levamisole had the highest acetylcholinesterase inhibitory actions among the tested drugs, and these drugs inhibited by 68...
May 2024: Drug Development Research
#32
JOURNAL ARTICLE
Ahmed Imtiaz, Shotaro Shimonaka, Mohammad Nasir Uddin, Montasir Elahi, Koichi Ishiguro, Masato Hasegawa, Nobutaka Hattori, Yumiko Motoi
The efficacy of current treatments is still insufficient for Alzheimer's disease (AD), the most common cause of Dementia. Out of the two pathological hallmarks of AD amyloid-β plaques and neurofibrillary tangles, comprising of tau protein, tau pathology strongly correlates with the symptoms of AD. Previously, screening for inhibitors of tau aggregation that target recombinant tau aggregates have been attempted. Since a recent cryo-EM analysis revealed distinct differences in the folding patterns of heparin-induced recombinant tau filaments and AD tau filaments, this study focused on AD seed-dependent tau aggregation in drug repositioning for AD...
2024: Frontiers in Aging Neuroscience
#33
Chang Wang, Aokun Chen, Xing He, Patrick Balian, Thomas J George, Fei Wang, Jiang Bian, Yi Guo
This study investigates the impact of clinical trial eligibility criteria on patient survival and serious adverse events (SAEs) in colorectal cancer (CRC) drug trials using real-world data. We utilized the OneFlorida+ network's data repository, conducting a retrospective analysis of CRC patients receiving FDA-approved first-line metastatic treatments. Propensity score matching created balanced case-control groups, which were evaluated using survival analysis and machine learning algorithms to assess the effects of eligibility criteria...
April 3, 2024: medRxiv
#34
JOURNAL ARTICLE
Makenna Ash, Meira Zibitt, Orr Shauly, Ambika Menon, Albert Losken, Daniel Gould
Topical antiaging therapies provide noninvasive delivery of active therapeutics. Exosomes, or extracellular nanovesicles, and peptides, small strings of amino acids, have shown promise as topical therapies in early trials, but neither is FDA approved. This review aims to elucidate the current and future landscape of topical exosomes and peptides as therapeutics for skin rejuvenation. A literature search was conducted using the keywords "peptides" OR "exosomes" AND "skin" OR "rejuvenation." Primary endpoints included mechanisms of action in humans or live animals as well as clinical data supporting the use of exosomes or peptides topically for skin rejuvenation or wound healing...
2024: Aesthetic surgery journal. Open forum
#35
REVIEW
Bashir Ahmad, Chuan Tian, Ji-Xin Tang, John Sieh Dumbuya, Wen Li, Jun Lu
Cancer is the main cause of death in the world. There are several therapies that are in practice for cancer cure including radiotherapy, chemotherapy, and surgery. Among the chemotherapies, natural products are considered comparable safe, easily available and cost effective. Approximately 60% of cancer approved FDA drugs are natural products including vinblastine, doxorubicin, and paclitaxel. These natural products have complex structures due to which they work against cancer through different molecular pathways, STAT3, NF-kB, PI3K/AKT/mTOR, cell cycle arrest, mitochondrial dependent pathway, extrinsic apoptosis pathway, autophagy, mitophagy and ferroptosis...
2024: Frontiers in Pharmacology
#36
REVIEW
Ezgi Pehlivanlar, Simone Carradori, Rahime Simsek
Migraine is a disease of neurovascular origin that affects the quality of life of more than one billion people and ranks sixth among the most common diseases in the world. Migraine is characterized by a moderate or severe recurrent and throbbing headache, accompanied by nausea, vomiting, and photo-phonophobia. It usually starts in adolescence and is twice as common in women as in men. It is classified as with or without aura and has chronic or acute treatment types according to the frequency of occurrence. In acute treatment, analgesics that relieve pain in the fastest way are preferred, while there are different options in chronic treatment...
April 12, 2024: ACS Pharmacology & Translational Science
#37
JOURNAL ARTICLE
Udit Nindra, Peter Lin, Therese Becker, Tara L Roberts, Wei Chua
Prostate cancer remains one of the leading causes of cancer-related death in the world. There have been significant advances in chemotherapy, hormonal therapy and targeted therapy options for patients with castrate-resistant disease. However, these systemic treatments are often associated with unwanted toxicities. Targeted therapy with radiopharmaceuticals has become of key interest to limit systemic toxicity and provides a more precision oncology approach to treatment. Strontium-89, Samarium-153 EDTMP and Radium-223 have been trialled with mixed results...
April 17, 2024: Journal of Medical Imaging and Radiation Oncology
#38
(no author information available yet)
No abstract text is available yet for this article.
April 2024: Nature Biotechnology
#39
JOURNAL ARTICLE
Wentao Wang, Siyu Qiu, Tianyi Zhang, Zhiwei Zheng, Kongkai Zhu, Xing Gao, Fengping Zhao, Xinyuan Ma, Hongyan Lin, Yingzi He, Canhui Zheng
Hearing loss (HL) is a health burden that seriously affects the quality of life of cancer patients receiving platinum-based chemotherapy, and few FDA-approved treatment specifically targets this condition. The main mechanisms that contribute to cisplatin-induced hearing loss are oxidative stress and subsequent cell death, including ferroptosis revealed by us as a new mechanism recently. In this study, we employed the frontier molecular orbital (FMO) theory approach as a convenient prediction method for the glutathione peroxidase (GPx)-like activity of isoselenazolones and discovered new isoselenazolones with great GPx-like activity...
April 12, 2024: European Journal of Medicinal Chemistry
#40
JOURNAL ARTICLE
Sung-Mok Jung, Sara L Loo, Emily Howerton, Lucie Contamin, Claire P Smith, Erica C Carcelén, Katie Yan, Samantha J Bents, John Levander, Jessi Espino, Joseph C Lemaitre, Koji Sato, Clifton D McKee, Alison L Hill, Matteo Chinazzi, Jessica T Davis, Kunpeng Mu, Alessandro Vespignani, Erik T Rosenstrom, Sebastian A Rodriguez-Cartes, Julie S Ivy, Maria E Mayorga, Julie L Swann, Guido España, Sean Cavany, Sean M Moore, T Alex Perkins, Shi Chen, Rajib Paul, Daniel Janies, Jean-Claude Thill, Ajitesh Srivastava, Majd Al Aawar, Kaiming Bi, Shraddha Ramdas Bandekar, Anass Bouchnita, Spencer J Fox, Lauren Ancel Meyers, Przemyslaw Porebski, Srini Venkatramanan, Aniruddha Adiga, Benjamin Hurt, Brian Klahn, Joseph Outten, Jiangzhuo Chen, Henning Mortveit, Amanda Wilson, Stefan Hoops, Parantapa Bhattacharya, Dustin Machi, Anil Vullikanti, Bryan Lewis, Madhav Marathe, Harry Hochheiser, Michael C Runge, Katriona Shea, Shaun Truelove, Cécile Viboud, Justin Lessler
BACKGROUND: Coronavirus Disease 2019 (COVID-19) continues to cause significant hospitalizations and deaths in the United States. Its continued burden and the impact of annually reformulated vaccines remain unclear. Here, we present projections of COVID-19 hospitalizations and deaths in the United States for the next 2 years under 2 plausible assumptions about immune escape (20% per year and 50% per year) and 3 possible CDC recommendations for the use of annually reformulated vaccines (no recommendation, vaccination for those aged 65 years and over, vaccination for all eligible age groups based on FDA approval)...
April 17, 2024: PLoS Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
